Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05307809
Recruiting Not applicable

Cytokine Expression in Psoriasis Patients With and Without Joint Involvement

NCT05307809 · tracked via the Priya Life Science France tracker
Sponsor
Poitiers University Hospital
Phase
Not applicable
Started
2022-08-17
Last updated
2026-08-31

Condition(s) studied

PsoriasisPsoriatic Arthritis

Investigational drug(s) / intervention(s)

Blood sample collectionSkin sample collection

Blood sample collection: Blood sample collection

Skin sample collection: Skin sample collection

Study summary

The objective of the resarch is to study the cytokine profile of patients with psoriatic arthritis and psoriasis in order to better understand the pathophysiology of the disease and the contribution of cytokines to the presence or absence of joint involvement. This research will compare cytokines levels in sera, in PBMC culture after LPS or CD3/CD28 agonist antibodies, and in skin biopsy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
Accepted
Inclusion criteria: * For psoriasis patients : * Age over 18 years old * Signed informed consent * 5 year old psoriasis at least * At least one skin lesion over 2 cm * Without any articular symptoms * Without any DMARDs * Without anticoagulant treatments or coagulation disease * With normal articular and enthesis sonography * For psoriatic arthritis patients : * Age over 18 years old * Signed informed consent * Psoriatic arthritis according to CASPAR criteria * Without any DMARDs * Without anticoagulant treatments or coagulation disease * With at least one synovitis at inclusion * For controls * Age and sex matched with a patient without any rheumatic or dermatologic medical conditions * No treatment with corticosteroïds or non-steroïdial anti-inflammatory drugsAge over 18 years old Exclusion criteria: ▪ For psoriasis patients : * Joint damage according to CASPAR criteria * Echography activity in favor of chronic inflammatory rheumatism * For patients and controls: * Without social protection rights * People under judiciary protection, of less than 18 years old, pregnant woman, breast feeding women, jailed patients.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chu Poitiers Poitiers France Recruiting

More Poitiers University Hospital trials in France

MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis Recruiting
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). Active, not recruiting
International Chronic Myeloid Leukemia Pediatric Study Recruiting
CARdiAc Mri and BiOLogical samplEs at the Acute Phase of a Myocardial Infarction (CARAMBOLE) Active, not recruiting
Confirmation of the Link Between Endocrine Disruptors Exposure and Breast Cancer and Identification of Biological Response Biomarkers Starting soon

Other trials for the same condition

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs Active, not recruiting
A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps Active, not recruiting
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect) Recruiting
HLA B Leader in Patients With Psoriatic Arthritis Recruiting
Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05307809 on ClinicalTrials.gov ↗ ← All trials in France